Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy -status quo

Mycoses

Volumn 55, Issue 3, 2012, Pages

  Rajeshkumar, Radhakrishnan ^a   Sundararaman, Muthuraman ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

Author keywords

Antifungal agents; Candida albicans; Clinical trials; Natural sources; Non albicans Candida; Patents

Indexed keywords

9ALPHA,11ALPHA EPOXYCHOLEST 7 ENE 3BETA,5ALPHA,6ALPHA,19 TETROL 6 ACETIC ACID; ALKALOID; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICATIC ACID A; CORTICATIC ACID B; CORTICATIC ACID E; FATTY ACID ESTER; MACROLIDE; MICAFUNGIN; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PLUMBAGIN; POLYKETIDE; SAPONIN DERIVATIVE; SORDARIN; UNCLASSIFIED DRUG; ZATARIA MULTIFLORA EXTRACT;

ACORUS CALAMUS; ALGA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDIASIS; CASUARINA EQUISTIFOLIA; CYANOBACTERIUM; DRUG LEGISLATION; DYSIDEA; DYSIDEA ARENARIA; EMBLICA OFFICINALIS; EUCALYPTUS; FICUS RELIGIOSA; GARLIC; HEMIDESMUS INDICUS; HOLARRHENA; HOLARRHENA ANTIDYSENTERICA; HUMAN; LAWSONIA INERMIS; MEDICINAL PLANT; MYXOCOCCALES; NELUMBO NUCIFERA; NONHUMAN; OCIMUM TENUIFLORUM; PATENT; PETROSIA; PETROSIA CORTICATA; PLUMBAGO (PLANT); PLUMBAGO SCANDENS; PLUMBAGO ZEYLANICA; POMEGRANATE; PRIORITY JOURNAL; SAPINDACEAE; SAUSSUREA LAPPA; SPONGE (PORIFERA); STREPTOMYCES; SWEET ORANGE; SYZGIUM AROMATICUM; TERMINALIA BELLIRICA; TERMINALIA CHEBULA; TRADITIONAL MEDICINE; ZATARIA MULTIFLORA;

ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL FACTORS; CANDIDA; CANDIDIASIS; DRUG DISCOVERY; HUMANS;

ALGAE; CANDIDA; CANDIDA ALBICANS;

EID: 84860014053     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02156.x     Document Type: Article

References (124)

1. Noble SM, Johnson AD. Genetics of Candida albicans, a diploid human fungal pathogen. Annu Rev Genet 2007; 41: 193-211.
2. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigates. J Clin Microbiol 2004; 42: 4419-31.
3. Demain AL, Sanchez S. Microbial drug discovery: 80years of progress. J Antibiot 2009; 62: 5-16.
4. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp. Report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006; 44: 1782-7.
5. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961-71.
6. Corsello S, Spinillo A, Osnengo G. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 66-67.
7. Runyoro DKB, Matee MIN, Ngassapa OD, Joseph CC, Mbwambo ZH. Screening of Tanzanian medicinal plants for anti-Candida activity. BMC Complem Altern M 2006; 6: 11.
8. Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med 2008; 59: 361-79.
9. Saini ML, Saini R, Roy S, Kumar A. Comparative pharmacognostical and antimicrobial studies of Acacia species (Mimosaceae). J Med Plants Res 2008; 12: 378-86.
10. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
11. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol 1998; 11: 382-402.
12. Cowen LE, Anderson JB, Kohn LM. Evolution of drug resistance in Candida albicans. Annu Rev Microbiol 2002; 56: 139-65.
13. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-80.
14. Gupte M, Kulkarni P, Ganguli BN. Antifungal antibiotics. Appl Microbiol Biotechnol 2002; 58: 46-57.
15. Iyer SV. Antifungal agents - past, present and future possibilities. In: Varma RS, Khan IK, Singh AP (eds), Antifungal Agents Past, Present, Future Prospect. Lucknow: National Academy of Chemistry and Biology, 1998; 3-26.
16. Ahmad I, Beg AZ. Antimicrobial and phytochemical studies on 45 Indian medicinal plants against multi-drug resistant human pathogens. J Ethnopharmacol 2001; 74: 113-23.
17. Duraipandiyan V, Ayyanar M, Ignacimuthu S. Antimicrobial activity of some ethnomedicinal plants used by Paliyar tribe from Tamil Nadu, India. BMC Complem Altern M 2006; 6: 35.
18. Satya VK, Radha Jeyalakshmi R, Kavitha K, Paranidharan V, Bhaskaran R, Velazhahan R. In vitro antimicrobial activity of zimmu (Allium sativum L.; Allium cepa L.) leaf extract. Arch Phytopathol Plant Prot 2005; 38: 185-92.
19. Yang CR, Zhang Y, Jacob MR, Khan SI, Zhang YJ, Li XC. Antifungal activity of C-27 steroidal saponins. Antimicrob Agents Chemother 2006; 50: 1710-4.
20. de Paiva SR, Figueiredo MR, Aragao TV, Kaplan MAC. Antimicrobial activity in vitro of Plumbagin isolated from Plumbago species. Mem Inst Oswaldo Cruz 2003; 98: 959-61.
21. Mahmoudabadi AZ, Dabbagh MA, Fouladi Z. In vitro anti-Candida activity of Zataria multiflora Boiss. eCAM 2007; 4: 351-3.
22. Okore VC, Ugwu CM, Oleghe PO, Akpa PA. Selective anti-candidal action of crude aqueous pod extract of Lecaniodiscus cupanioides: a preliminary study on Candida albicans obtained from an AIDS patient. Sci Res and Essay 2007; 2: 43-46.
23. Botelho MA, Nogueira NAP, Bastos GM et al. Antimicrobial activity of the essential oil from Lippia sidoides, carvacrol and thymol against oral pathogens. Braz J Med Biol Res 2007; 40: 349-56.
24. Khan Rosina, Islam Barira, Akram Mohd et al. Antimicrobial activity of five herbal extracts against multi drug resistant (MDR) strains of bacteria and fungus of clinical origin. Molecules 2009; 14: 586-97.
25. Pinto E, Vale-Silva L, Cavaleiro C, Salgueiro L. Antifungal activity of the clove essential oil from Syzygium aromaticum on Candida, Aspergillus and dermatophyte species. J Med Microbiol 2009; 58: 1454-62.
26. Valsaraj R, Pushpangadan P, Smitt UW et al. New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. J Nat Prod 1997; 60: 739-42.
27. Okemo PO, Mwatha WE, Chhabrab SC, Fabry W. The kill kinetics of Azadirachta indica A. JUSS. (meliaceae) extracts on Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans. Afr J Sci Technol 2001; 2: 113-8.
28. Dahanukar SA, Kulkarni RA, Rege NN. Pharmacology of medicinal plants and natural products. Indian J Pharmacol 2000; 32: S81-118.
29. Makinde AA, Igoli JO, TA Ama L., Shaibu SJ, Garba A. Antimicrobial activity of Cassia alata. Afr J Biotechnol 2007; 6: 1509-10.
30. Moshahid M, Rizvi A, Irshad M, Hassadi GE, Younis SB. Bioefficacies of Cassia fistula: an Indian labrum. Afr J Pharm Pharmacol 2009; 3: 287-92.
31. Panda SK, Brahma S., Dutta SK. Selective antifungal action of crude extracts of Cassia fistula L.: a preliminary study on Candida and Aspergillus species. Malays J Microbiol 2010; 6: 62-8.
32. Duraipandiyan V, Ignacimuthu S. Antibacterial and antifungal activity of Cassia fistula L.: an ethnomedicinal plant. J Ethnopharm 2007; 112: 590-4.
33. Aburjai T, Hudaib M. Antiplatelet, antibacterial and antifungal activities of Achillea falcata extracts and evaluation of volatile oil composition. Pharmacogn Mag 2006; 2: 191-8.
34. Al-Bayati FA, Sulaiman KD. In vitro antimicrobial activity of Salvadora persica L. Extracts against some isolated oral pathogens in Iraq. Turk J Biol 2008; 32: 57-62.
35. Pauli A, Schilcher H. Specific selection of essential oil compounds for treatment of children's infection diseases. Pharmaceuticals 2004; 1: 1-30.
36. Dzubak P, Hajduch M, Vydra D et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 2006; 23: 394-411.
37. Patel M, Coogan MM. Antifungal activity of the plant Dodonaea viscosa var. angustifolia on Candida albicans from HIV-infected patients. J Ethnopharmacol 2008; 118: 173-6.
38. Vazquez JA, Arganoza MT, Boikov D, Vaishampayan JK, Akins RA. In vitro susceptibilities of Candida and Aspergillus species to Melaleuca alternafolia (tea tree) oil. Rev Iberoam Micol 2000; 17: 60-3.
39. Mondello F, De Bernardis F, Girolamo A, Cassone A, Salvatore G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect Dis 2006; 6: 158.
40. Phongpaichit S. Antimicrobial activity of Cinnamomum porrectum oil. Songklanakarin J Sci Technol 2006; 29: (Suppl. 1): 11-16. Thai Herbs II
41. Vinitha M, Ballal M. In vitro anticandidal activity of Cinnamomum verum. J Med Sci 2008; 8: 425-8.
42. Oladosu IA, Zubair MF, Ali MS, Olawore NO. Anticandidal activity of volatile compounds from the root bark of Ficus exasperata Vahl-Holl (Moraceae). J Essent Oil Bear Plants 2009; 12: 562-8.
43. Bastos MLA, Lima MRF, Conserva LM, Andrade VS, Rocha EMM, Lemos RPL. Studies on the antimicrobial activity and brine shrimp toxicity of Zeyheria tuberculosa (Vell.) Bur. (Bignoniaceae) extracts and their main constituents. Ann Clin Microbiol Antimicrob 2009; 8: 16.
44. Hwang EI, Kwon BM, Lee SH et al. Obovatols, new chitin synthase 2 inhibitors of Saccharomyces cerevisiae from Magnolia obovata. J Antimicrob Chemother 2002; 49: 95-101.
45. Park KS, Kang KC, Kim JH, Adams DJ, Johng TN, Paik YK. Differential inhibitory effects of protobernerines on sterol and chitin biosynthesis in Candida albicans. J Antimicrob Chemother 1999; 43: 667-74.
46. Huffords CD, Hihchihli U, Clar A. Anticandidal activity of eupolauridine and onychine, alkaloids from Cleistopholis patens. J Nat Prod 1987; 50: 961-4.
47. Zhang H, Gao A, Li F, Zhang G, Ho HI, Liao W. Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps. Yakugaku Zasshi 2009; 129: 623-30.
48. Ghannoum MA. Studies on the anticandidal mode of action of Allium sativum (garlic). J Gen Microbiol 1988; 134: 2917-24.
49. Hughes BG, Lawson LD. Antimicrobial effects of Allium sativum L. (garlic), Allium ampeloprasum L. (elephant garlic), and Allium cepa L. (onion), garlic compounds and commercial garlic supplement products. Phytother Res 1991; 5: 154-8.
50. Pinto E, Pina-Vaz C, Salgueiro L et al. Antifungal activity of the essential oil of Thymus pulegioides on Candida, Aspergillus and dermatophyte species. J Med Microbiol 2006; 55: 1367-73.
51. Shin S, Kang CA. Antifungal activity of the essential oil of Agastache rugosa Kuntze and its synergism with ketoconazole. Lett Appl Microbiol 2003; 36: 111-5.
52. Ogundiya MO, Kolapo AL, Okunade MB, Adejumobi JA. Evaluation of phytochemical composition and antimicrobial activity of Terminalia glaucescens against some oral pathogens. Adv Nat Appl Sci 2008; 2: 89-93.
53. Noumi E, Snoussi M, Hajlaoui H, Valentin E, Bakhrouf A. Antifungal properties of Salvadora persica and Juglans regia L. extracts against oral Candida strains. Eur J Clin Microbiol Infect Dis 2010; 29: 81-8.
54. Amber K, Aijaza A, Immaculatab X, Luqmana KA, Nikhat M. Anticandidal effect of Ocimum sanctum essential oil and its synergy with fluconazole and ketoconazole. Phytomedicine 2010; 17: 921-5.
55. Begnami AF, Duarte MCT, Furletti V, Rehder VLG. Antimicrobial potential of Coriandrum sativum L. against different Candida species in vitro. Food Chem 2010; 118: 74-7.
56. Rybalchenko NP, Prykhodko VA, Nagorna SS et al. In vitro antifungal activity of phenylheptatriyne from Bidens cernua L. against yeasts. Fitoterapia 2010; 81: 336-8.
57. Mbosso EJT, Ngouela S, Nguedia JCA, Beng VP, Rohmer M, Tsamo E. In vitro antimicrobial activity of extracts and compounds of some selected medicinal plants from Cameroon. J Ethnopharmacol 2010; 128: 476-81.
58. Mahboubi M, Ghazian Bidgoli F. In vitro synergistic efficacy of combination of amphotericin B with Myrtus communis essential oil against clinical isolates of Candida albicans. Phytomedicine 2010; 17: 771-4.
59. Nchu F, Aderogba MA, Mdee LK, Eloff JN. Isolation of anti-Candida albicans compounds from Markhamia obtusifolia (Baker) Sprague (Bignoniaceae). S Afr J Bot 2010; 76: 54-57.
60. Endo EH, Cortez DAG, Ueda-Nakamura T, Nakamura CV, Dias Filho BP. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans. Res Microbiol 2010; 161: 534-40.
61. Sanguinetti M, Posteraro B, Romano L et al. In vitro activity of Citrus bergamia (bergamot) oil against clinical isolates of dermatophytes. J Antimicrob Chemother 2007; 59: 305-8.
62. Noumi E, Snoussi M, Bakhrouf A. In vitro effect of Melaleuca alternifolia and Eucalyptus globulus essential oils on mycelia formation by oral Candida albicans strains. Afr J Microbiol Res 2010; 4: 1332-6.
63. Grabley S, Sattler I. Natural products for lead identification: nature is a valuable resource for providing tools. Hillisch A, Hilgenfeld R (eds). Modern Methods of Drug Discovery. Basel, Switzerland: Birkhauser Verlag, 2003: 87-108.
64. Vicente MF, Basilio A, Cabello A, Pelaez F. Microbial natural products as a source of antifungals. Clin Microbiol Infect 2003; 9: 15-32.
65. Vicente F, Basilioa A, Platasa G et al. Distribution of the antifungal agents sordarins across filamentous fungi. Mycol Res 2009; 113: 754-70.
66. Kanasaki R, Abe F, Furukawa S et al. FR209602 and related compounds, novel antifungal lipopeptides from Coleophoma crateriformis No. 738. J Antibiot 2006; 59: 145-8.
67. Gong LJ, Guo SX. Endophytic fungi from Dracaena cambodiana and Aquilaria sinensis and their antimicrobial activity. Afr J Biotechnol 2009; 8: 731-6.
68. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004; 64: 969-82.
69. Abruzzo GK, Gill CJ, Flattery AM et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000; 44: 2310-8.
70. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-21.
71. Rodriguez-Meizoso I, Jaime L, Santoyo S et al. Pressurized fluid extraction of bioactive compounds from Phormidium species. J Agric Food Chem 2008; 56: 3517-23.
72. Jaiswal P, Singh PK, Prasanna R. Cyanobacterial bioactive molecules - an overview of their toxic properties. Can J Microbiol 2008; 54: 701-17.
73. Paul VJ, Ritson-Williams R. Marine chemical ecology. Nat Prod Rep 2008; 25: 662-95.
74. Burke C, Thomas T, Egan S, Kjelleberg S. The use of functional genomics for the identification of a gene cluster encoding for the biosynthesis of an antifungal tambjamine in the marine bacterium Pseudoalteromonas tunicate. Environ Microbiol 2007; 9: 814-8.
75. Takesako K, Kuroda H, Inoue T et al. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J Antibiot 1993; 46: 1414-20.
76. Aoki Y, Kondoh M, Nakamura M et al. A new methionine antagonist that has antifungal activity: mode of action. J Antibiot 1994; 47: 909-16.
77. Kaleli I, Cevahir N, Demir M, Yildirim U, Sahin R. Anticandidal activity of Pseudomonas aeruginosa strains isolated from clinical specimens. Mycoses 2007; 50: 74-8.
78. Chin YW, Balunas MJ, Chai HB, Douglas KA. Drug discovery from natural sources. AAPS J 2006; 8: E239-53.
79. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 2006; 55: 999-1008.
80. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
81. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007; 369: 1519-27.
82. Iwalokun BA., Usen UA, Otunba AA, Olukoya DK. Comparative phytochemical evaluation, antimicrobial and antioxidant properties of Pleurotus ostreatus. Afr J Biotechnol 2007; 6: 1732-9.
83. Solomko EF, Eliseeva GS. Biosynthesis of vitamins B by the fungus Pleurotus ostreatus in a submerged culture. Prikl Biokhim Mikrobiol 1988; 24: 164-9.
84. Dikeman CL, Bauer LL, Flickinger EA, Fahey GC Jr. Effects of stage of maturity and cooking on the chemical composition of select mushroom varieties. J Agric Food Chem 2005; 53: 1130-8.
85. Valentao P, Andrade PB, Rangel J et al. Effect of the conservation procedure on the contents of phenolic compounds and organic acids in chanterelle (Cantharellus cibarius) mushroom. J Agric Food Chem 2005; 53: 4925-31.
86. Rosa LH, Machado KMG, Jacob CC, Capelari M, Rosa CA, Zani CL. Screening of Brazilian basidiomycetes for antimicrobial activity. Mem Inst Oswaldo Cruz 2003; 98: 967-74.
87. Yan Y, Huang L, Miao S. Occurrence of the epizoic barnacle Octolasmis angulata on the crab Charybdis feriatus from Daya Bay, China. J Mar Biol Assoc UK 2004; 84: 619-20.
88. Bhadury P, Wright PC. Exploitation of marine algae: biogenic compounds for potential antifouling applications. Planta 2004; 219: 561-78.
89. Sasidharan S, Darah I, Jain K. In vivo and in vitro toxicity study of Gracilaria changii. Pharma Biol 2008; 46: 413-7.
90. Burja AM, Banaigs B, Abou-Mansour E, Burgess JG, Wright PC. Marine cyanobacteria a prolific source of natural products. Tetrahedron 2001; 57: 9347-77.
91. Selvin J, Shanmughapriya S, Gandhimathi R et al. Optimization and production of novel antimicrobial agents from sponge associated marine actinomycetes Nocardiopsis dassonvillei MAD08. Appl Microbiol Biotechnol 2009; 83: 435-45.
92. El-Amraoui B, Biard JF, Uriz MJ, Rifai S, Fassouane A. Antifungal and antibacterial activity of Porifera extracts from the Moroccan Atlantic coasts. J Mycol Med 2010; 20: 70-4.
93. Rifai S, Fassouane A, Kijjoa A, Van Soest R. Antimicrobial Activity of untenospongin B, a metabolite from the marine sponge Hippospongia communis collected from the Atlantic coast of Morocco. Mar Drugs 2004; 2: 147-53.
94. Jacob MR, Hossain CF, Mohammed KA et al. Reversal of fluconazole resistance in multidrug efflux-resistant fungi by the Dysidea arenaria sponge sterol 9α, 11α-epoxycholest-7-ene-3β, 5α, 6α, 19-tetrol 6-acetate. J Nat Prod 2003; 66: 1618-22.
95. Mayer AMS, Rodriguez AD, Berlinck RGS, Hamann MT. Marine pharmacology in 2003-4: Marine compounds with anthelminthic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2007; 145: 553-81.
96. Kossuga MH, MacMillan JB, Rogers EW et al. (2S, 3R)-2-aminododecan-3-ol, a new antifungal agent from the ascidian Clavelina oblonga. J Nat Prod 2004; 67: 1879-18810.
97. Li HY, Matsunaga S, Fusetani N. Corticatic acids A-C, antifungal acetylenic acids from the marine sponge, Petrosia corticata. J Nat Prod 1994; 57: 1464-7.
98. Nishimura S, Matsunaga S, Shibazaki M et al. Massadine, a novel geranylgeranyltransferase type I inhibitor from the marine sponge Stylissa aff. Massa Org Lett 2003; 5: 2255-7.
99. Nakao Y, Fusetani N. Enzyme inhibitors from marine invertebrates. J Nat Prod 2007; 70: 689-710.
100. Parthasarathi B, Gupta BM, Garg KC. Patent statistics as indicator of competition an analysis of patenting in biotechnology. Scientometrics 2000; 47: 95-116.
101. Sekar S, Paulraj P. Strategic mining of cyanobacterial patents from the USPTO patent database and analysis of their scope and implications. J Appl Phycol 2006; 19: 277-92.
102. O'Sullivan J, Phillipson DW, Straub H, Ermann PH. 4-Methoxy-5-methyl-pyran-3-ol natural products and derivatives thereof. U.S. Patent 5270334 (14 Dec 1993).
103. Hufford CD, Clark AM. Antimicrobial compound and compositions particularly effective against Candida albicans. U.S. Patent 4873250 (10 Oct 1989).
104. Bobek LA. d-Isomers of antimicrobial peptide. U.S. Patent 7271239 B2 (18 Sep 2007).
105. Pettit GR. Antifungal activity of the spongistatins. U.S. Patent 5883120 (16 Mar 1999).
106. West B, Jensen CJ, Palu AK, Ogden R, Gerson S. Method and formulation for treating candidiasis using Morinda citrifolia. U. S. Patent 2009/0053336 A1 (26 Feb 2009).
107. Gorman JA, O' Sullivan J, Leet JE, Mamber SW. Ascosteroside and analogs thereof useful in antifungal compositions for methods of treating infections and inhibition of fungal growth. U. S. Patent 5521169 (28 May 1996).
108. Khanuja SPS, Tiruppadiripuliyur RS, Gupta VK et al. Antimicrobial and anticancer properties of methyl-beta-orcinolcarboxylate from lichen (Everniastrum cirrhatum). U. S. Patent 2007/0099993 A1 (3 May 2007).
109. Martinez-Miller C, Miller RV, Strobel GA. Antifungal compounds from Pseudomonas viridiflava. U.S. Patent 6103875 (15 Aug 2000).
110. Gibson DJ, Carlson RM. Methods of treating fungal infections using Lupeol. U. S. Patent 2005/6951847 (4 Oct 2005).
111. Kulanthaivel P, Belvo MD, Martin JW, Thomas JP Jr, Zeckner DJ. Pseudomycin natural products. U. S. Patent 6793925 B2 (21 Sep 2004).
112. Majeed M, Prakash S. Composition and methods containing an antimicrobial essential oil extracted from Coleus forskohilii. U. S. Patent 2002/0160066 A1 (31 Oct 2002).
113. Kandil O. Sterol fractions of Nigella sativa L. Seeds. U.S. Patent 2002/0132019 A1 (19 Sep 2002).
114. Yamada Y, Sakudu S, Takayama S. Allosamidin compounds. U.S. Patent 5413991 (9 May 1995).
115. Masubuchi M, Okudu T, Shimada H. Microorganism of genus Eupenicillium. U.S. Patent 5292648 (8 Mar 1994).
116. Fountoulakis JM, Masurekar PS. Process for production of an antibiotic compound using Zalerion arboricola. U.S. Patent 5137813 (11 Aug 1992).
117. Pan S, Shen L, Kang Y et al. Radix bupleuri extract and antibiotic use thereof. C.N. Patent 101310731 (26 Nov 2008).
118. Rolland Y, Duval C. Novel uses of Hibiscus, in particular pharmaceuticals uses. W.O. Patent 2008/148995 (11 Dec 2008).
119. Husmark U, Forsgren Brusk U, Grahn Hakansson E, Ronnqvist D. Lactobacillus Fermentum ESS-1, DSM17851 and its use for the treatment and/or prevention of Candidiasis and Urinary tract infections. W. O. Patent 2008/060198 (22 May 2008).
120. Long K. Modified coconut oils with broad antimicrobial spectrum. U. S. Patent 2010/0016430 A1 (21 Jan 2010).
121. Schlingmann G, Milne L, Pearce CJ, Gareth Jones EB, Albaugh DA. Fungicidal agents LL-15G256 γ, δ and ε produced by LL-15G256 (Hypoxylon oceanicum). U. S. Patent 5747304 (5 May 1998).
122. Friedman LM, Furberg CD, De Mets DL. Fundamentals of Clinical Trials, 3rd edn. New York: Springer-Verlag, 1988; 361pp: ISBN 0-387-98586-7.
123. de Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-9.
124. Kubiak DW, Bryar JM, McDonnell AM et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 32 2010; 4: 637-48.